Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
FDA released a revised draft guidance on assessing irritation and sensitization potential for transdermal and topical delivery systems in ANDAs, which may affect testing requirements for generic drug approvals.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic drug manufacturers (ANDA applicants) developing transdermal and topical products, including those with abbreviated new drug applications. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments on the draft guidance are due by [date not specified in excerpt; check Federal Register notice for comment deadline].. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a revised draft guidance providing updated recommendations on studies to assess skin irritation and sensitization potential for transdermal and topical delivery systems submitted in ANDAs.
Who it affects
Generic drug manufacturers (ANDA applicants) developing transdermal and topical products, including those with abbreviated new drug applications.
What you must do
Review the revised draft guidance to understand updated recommendations and assess potential impact on ongoing or planned ANDA development programs.
Deadline
Comments on the draft guidance are due by [date not specified in excerpt; check Federal Register notice for comment deadline].
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - vitallaw.com
- WY HB0013: Ivermectin-no prescription required.